SOPHiA GENETICS SA (NASDAQ:SOPH) Expected to Post Earnings of -$0.33 Per Share

Equities research analysts predict that SOPHiA GENETICS SA (NASDAQ:SOPHGet Rating) will post earnings of ($0.33) per share for the current quarter, Zacks reports. Three analysts have issued estimates for SOPHiA GENETICS’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.30). The business is scheduled to issue its next earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that SOPHiA GENETICS will report full-year earnings of ($1.43) per share for the current financial year, with EPS estimates ranging from ($1.44) to ($1.41). For the next year, analysts forecast that the firm will post earnings of ($1.33) per share, with EPS estimates ranging from ($1.46) to ($1.20). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow SOPHiA GENETICS.

SOPHiA GENETICS (NASDAQ:SOPHGet Rating) last announced its earnings results on Tuesday, March 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $10.94 million during the quarter, compared to analysts’ expectations of $11.27 million. SOPHiA GENETICS had a negative net margin of 182.14% and a negative return on equity of 39.82%.

A number of equities research analysts have issued reports on the stock. Morgan Stanley reduced their price objective on shares of SOPHiA GENETICS from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 16th. Zacks Investment Research upgraded shares of SOPHiA GENETICS from a “sell” rating to a “hold” rating in a research report on Wednesday, March 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, SOPHiA GENETICS presently has a consensus rating of “Buy” and a consensus price target of $20.67.

A number of institutional investors and hedge funds have recently modified their holdings of SOPH. Pictet & Cie Europe SA acquired a new position in shares of SOPHiA GENETICS during the first quarter worth $1,759,000. Banque Pictet & Cie SA acquired a new stake in shares of SOPHiA GENETICS during the first quarter worth $16,205,000. Bank Pictet & Cie Asia Ltd. bought a new stake in SOPHiA GENETICS during the first quarter valued at $498,000. Lombard Odier Asset Management Switzerland SA grew its holdings in SOPHiA GENETICS by 0.8% during the 4th quarter. Lombard Odier Asset Management Switzerland SA now owns 146,844 shares of the company’s stock worth $2,071,000 after acquiring an additional 1,174 shares during the period. Finally, Citadel Advisors LLC bought a new position in shares of SOPHiA GENETICS in the 4th quarter worth about $200,000. 27.64% of the stock is owned by institutional investors and hedge funds.

SOPH opened at $6.30 on Friday. SOPHiA GENETICS has a 52-week low of $5.73 and a 52-week high of $19.80. The business’s fifty day moving average is $8.25 and its 200-day moving average is $11.63.

About SOPHiA GENETICS (Get Rating)

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide.

Further Reading

Get a free copy of the Zacks research report on SOPHiA GENETICS (SOPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.